Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Clinical Research 15: Clinical Research 5: Genitourinary Malignancy

FGFR3 mutations have different effects on disease course in tumors from the bladder, ureter, and renal pelvis

Johanna M. M. Van Oers, Ellen C. Zwarthoff, Ishtiaq Rehman, Abdel-Rahmene Azzouzi, Oliver Cussenot, Mark Meuth, Freddie C. Hamdy and James W. F. Catto
Johanna M. M. Van Oers
Erasmus MC, Rotterdam, The Netherlands, University of Sheffield, Sheffield, United Kingdom, University of Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellen C. Zwarthoff
Erasmus MC, Rotterdam, The Netherlands, University of Sheffield, Sheffield, United Kingdom, University of Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ishtiaq Rehman
Erasmus MC, Rotterdam, The Netherlands, University of Sheffield, Sheffield, United Kingdom, University of Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abdel-Rahmene Azzouzi
Erasmus MC, Rotterdam, The Netherlands, University of Sheffield, Sheffield, United Kingdom, University of Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Cussenot
Erasmus MC, Rotterdam, The Netherlands, University of Sheffield, Sheffield, United Kingdom, University of Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Meuth
Erasmus MC, Rotterdam, The Netherlands, University of Sheffield, Sheffield, United Kingdom, University of Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Freddie C. Hamdy
Erasmus MC, Rotterdam, The Netherlands, University of Sheffield, Sheffield, United Kingdom, University of Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James W. F. Catto
Erasmus MC, Rotterdam, The Netherlands, University of Sheffield, Sheffield, United Kingdom, University of Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2006
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 47, 2006

Abstract

4513

The urothelial lining of the upper and lower urinary tract is histologically identical and tumors of the upper and lower urinary tract show morphological similarities. Despite these similarities, genetic and epigenetic differences occur: microsatellite instability and promoter hypermethylation are more frequent and more extensively present in upper tract tumors (UTT), when compared to bladder tumors. Methylation is associated with advanced tumor stage and increased tumor progression and mortality rates. On the other hand, fibroblast growth factor receptor 3 (FGFR3) mutations have been found at a high frequency in bladder tumors of low stage and grade with a low risk of progression. We hypothesised that FGFR3 mutations occur at a lower frequency in UTT. We analysed 253 tumor samples, of which 106 were bladder tumors and 154 were UTT (both ureter and renal pelvis). FGFR3 mutations were detected by SNaPshot analysis. Analysis for hypermethylation at 11 CpG islands was performed using methylation sensitive PCR and bisulphite sequencing. FGFR3 mutations occur with the same frequency in bladder (46%, 49/106) and upper tract (49%, 75/154) tumors, and are associated with a milder disease course (less often progression, better survival) in both bladder and ureter tumors (p<0.001). However, in the group of 83 renal pelvis tumors this relation is less significant (p=0.04). This is concordant with the finding that FGFR3 mutation status is not significantly associated with tumor grade (p=0.2) in renal pelvis tumors. In UTT, methylation of the RASSF1A gene is more frequent in tumors without an FGFR3 mutation (p=0.03). The combination of FGFR3 and RASSF1A is related to disease progression and survival in bladder (p<0,001) and ureter (p=0.02) tumors, since patients with an FGFR3 mutant tumor show less often progression when RASSF1A is not methylated. This is not the case for patients with a tumour in the renal pelvis (p=0.2). We conclude that FGFR3 mutations occur at the same frequency in bladder tumors and UTT. In the case of bladder and ureter tumors, the FGFR3 mutation seems to protect the tumor from progressing, and methylation of RASSF1A further distinguishes between mutant tumors that show more (methylated) or less (unmethylated) progression. The FGFR3 mutation does not have the same effect in renal pelvis tumors.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 66 (8 Supplement)
April 2006
Volume 66, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
FGFR3 mutations have different effects on disease course in tumors from the bladder, ureter, and renal pelvis
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
FGFR3 mutations have different effects on disease course in tumors from the bladder, ureter, and renal pelvis
Johanna M. M. Van Oers, Ellen C. Zwarthoff, Ishtiaq Rehman, Abdel-Rahmene Azzouzi, Oliver Cussenot, Mark Meuth, Freddie C. Hamdy and James W. F. Catto
Cancer Res April 15 2006 (66) (8 Supplement) 1059;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
FGFR3 mutations have different effects on disease course in tumors from the bladder, ureter, and renal pelvis
Johanna M. M. Van Oers, Ellen C. Zwarthoff, Ishtiaq Rehman, Abdel-Rahmene Azzouzi, Oliver Cussenot, Mark Meuth, Freddie C. Hamdy and James W. F. Catto
Cancer Res April 15 2006 (66) (8 Supplement) 1059;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Aurora A test for bladder cancer
  • Sensitivity of renal cell carcinoma (RCC) cell lines to Sorafenib in vitro is dependent upon Akt and GSK3β activity
  • Infliximab, a humanised anti-TNF-a monoclonal antibody, exhibits biological activity in the ovarian tumor microenvironment in patients
Show more Clinical Research 15: Clinical Research 5: Genitourinary Malignancy
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement